Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
Akston Biosciences has initiated a once-weekly GLP-1 weight-management trial in cats at Cornells College of Veterinary Medicine
Studies have explored various dietary factors, but results have been inconclusive
This conversion must happen before applying weight-based dosing formulas
Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to CARNITOR
US$ 27.11
US$ 27.62
US$ 26.80
US$ 27.33
US$ 27.23
US$ 20.87
